Physician profile
Barbara Jacobs
NPI 1275981706
$5,319.34
in general payments reported to CMS, 2019-2025
29 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.10 · 2021: $13.17 · 2022: $1,304 · 2023: $1,455 · 2024: $1,144 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,572.01 | 2021-2025 | Enbrel, Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $526.98 | 2022-2024 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $492.44 | 2022-2025 | Saphnelo, Farxiga |
| Abbvie INC. | $465.13 | 2022-2025 | |
| Janssen Biotech, INC. | $369.83 | 2022-2024 | Simponi Aria, Tremfya |
| Pfizer INC. | $264.81 | 2023-2025 | |
| Insulet Corporation | $239.16 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $178.06 | 2022-2025 | Zepbound, Taltz, Mounjaro |
| Glaxosmithkline, LLC. | $169.35 | 2023-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.13 | 2022-2023 | Jardiance |
| Ani Pharmaceuticals, INC. | $138.83 | 2023 | Purified Cortrophin Gel |
| Masimo Corporation | $97.85 | 2022 | |
| Gilead Sciences, INC. | $94.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.86 | 2023-2025 | |
| Novo Nordisk INC | $68.17 | 2022-2025 | Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $52.79 | 2023-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $41.71 | 2022-2023 | |
| Aurinia Pharma U.S., INC. | $41.57 | 2022-2025 | Lupkynis |
| Corcept Therapeutics | $40.83 | 2023 | Korlym |
| Mannkind Corporation | $34.77 | 2022-2025 | |
| Chiesi USA, INC. | $31.96 | 2024 | Mycapssa |
| E.R. Squibb & Sons, L.L.C. | $24.74 | 2025 | Orencia |
| Boston Scientific Corporation | $24.01 | 2022 | |
| Ucb, INC. | $23.00 | 2024 | Cimzia |
| Xeris Pharmaceuticals, INC. | $22.89 | 2024 | Recorlev |
| Sobi, INC | $20.68 | 2024 | |
| Recordati_rare_diseases_inc. | $17.70 | 2023 | Isturisa, Signifor Lar |
| Genentech USA, INC. | $17.53 | 2024 | Actemra |
| Bayer Healthcare Pharmaceuticals INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.